We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Andrew Mason

Andrew L. Mason MBBS, FRCPI, FAASLD

Professor of Medicine, Division of Gastroenterology; Director, The Applied Genomic Core, Faculty of Medicine and Dentistry; Co-Director, Center of Excellence for Gastrointestinal Inflammation and Immunity Research, University of Alberta, Edmonton, Alberta, Canada

Dr. Mason is Professor of Medicine in the Division of Gastroenterology at the University of Alberta, Edmonton, Alberta. He is Director of the Applied Genomics Core in the Faculty of Medicine and Dentistry, Director of Gastrointestinal and Liver Disease Research, and Co-Director of the Center of Excellence for Gastrointestinal Inflammation and Immunity Research.

Dr. Mason has established a translational research program studying the role of a human betaretrovirus in patients with primary biliary cholangitis. The Mason laboratory currently evaluates different antiretroviral therapies in a mouse model of autoimmune biliary disease with betaretrovirus cholangitis. His group are currently developing diagnostic assays to detect immune responses to betaretrovirus infection in patients with autoimmune liver disease. He is Principal Investigator on a Canadian multi-center, randomized controlled trial assessing combination anti-retroviral therapy for patients with primary biliary cholangitis, and Co-Principal Investigator for the Canadian Network for Autoimmune Liver Disease studying demographic and prognostic features of primary biliary cholangitis and autoimmune hepatitis.

Disclosures

Dr. Mason shares ownership of North American and European patents for human betaretrovirus diagnostics and therapy.

Recent Contributions to PracticeUpdate:

  1. Obeticholic Acid for Primary Sclerosing Cholangitis